In a phase I/II clinical trial a replication incompetent adenovirus expressing mda-7/IL-24, Ad.mda-7 (INGN 241) (2 × 1010 to 2 × 1012 vp) was administered intratumorally in a cohort of 28 patients with melanomas and advanced carcinomas and injections were repeated in a dose-escalating manner. The gene discussed is IL24; the disease is melanoma.